KTRA / Kintara Therapeutics, Inc. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37823 TUHURA BIOSCIENCES, INC.

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named “TBS-2025;” planning to initiate a Phase 2

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named “TBS-2025;” planning to initiate a Phase 2 trial in relapsed/refractory NPM1-mutated Acute Myeloid Leukemia (AML) in combination with a menin inhibitor in 2H 2025 Initiated a Phase 3 accelerate

KINETA, INC. Condensed Consolidated Balance Sheets (in thousands) March 31, December 31, 2025 2024 Assets Current assets: Cash $ 304 $ 634 Restricted cash 4 4 Prepaid expenses and other current assets 534 381 Total current assets 842 1,019 Total asse

EX-99.1 Exhibit 99.1 KINETA, INC. Condensed Consolidated Balance Sheets (in thousands) (Unaudited) March 31, December 31, 2025 2024 Assets Current assets: Cash $ 304 $ 634 Restricted cash 4 4 Prepaid expenses and other current assets 534 381 Total current assets 842 1,019 Total assets $ 842 $ 1,019 Liabilities and Stockholders’ Equity (Deficit) Current liabilities: Accounts payable $ 4,886 $ 3,901

Filing fee table

Calculation of Filing Fee Tables S-1 TuHURA Biosciences, Inc./NV Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward

Power of Attorney (included on the signature page of the Registration Statement)

Table of Contents As filed with the Securities and Exchange Commission on [   ], 2025.

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Unless the context indicates otherwise in this Unaudited Pro Forma Consent Combined Financial Information, references to “TuHURA,” “TuHURA Biosciences, Inc.” the “Company,” “we,” “us,” “our” and similar terms refer to TuHURA Biosciences, Inc., a Nevada corporation (formerly known as Kintara Therapeutics, Inc. and our

Articles of Incorporation of TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.), as amended

EX-3.1 Exhibit 3.1

List of Subsidiaries

EX-21.1 Exhibit 21.1 List of Subsidiaries Adgero Biopharmaceuticals Holdings, Inc. (Delaware) Adgero Biopharmaceuticals, Inc. (Delaware) TuHURA Biosciences, Inc. (Delaware) Kineta, LLC (Delaware)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporati

TuHURA Biosciences Completes Acquisition of Kineta Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA’s late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA

Exhibit 99.1 TuHURA Biosciences Completes Acquisition of Kineta Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA’s late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in 2nd Half 2025 Completion of the acquisition unlocks the fourth tranche of funds from $12.5 million aggregate PIPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fi

Certificate of Amendment of Articles of Incorporation

Exhibit 3.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fi

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals TAMPA, Fla., and Seattle, Wash., June 23, 2025 — TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc. (OTC Pink:KANT) (“Kineta”), a cl

Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fil

Form of Warrant.

EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HA

Form of Securities Purchase Agreement.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 2, 2025, by and among TuHURA Biosciences, Inc., a Nevada corporation (the “Company”), and each of the entities executing signature pages to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering this Ag

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy Secur

Exhibit 99.1 TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy Secures $12.5 million of commitments in a private offering Secures an additional $3.0 million through payment of cash exercise price of warran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 TUHURA BIOSCIENCES,

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fil

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy Secur

Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: TuHURA Biosciences, Inc.

MERGER AGREEMENT PROPOSAL – YOUR VOTE IS VERY IMPORTANT

424B3 Table of Contents Filed Pursuant to 424(b)(3) Registration No. 333-284787 MERGER AGREEMENT PROPOSAL – YOUR VOTE IS VERY IMPORTANT Dear TuHURA Biosciences, Inc. Stockholders and Kineta, Inc. Stockholders: On December 11, 2024, TuHURA Biosciences, Inc., a Nevada corporation (“TuHURA”), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA (“Merger Sub I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fil

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fil

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update Anticipates initiating the Company’s Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update Anticipates initiating the Company’s Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) agreement with U.S. Food and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39473 TUHURA BIOSCIENCES, INC.

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: TuHURA Biosciences, Inc.

May 12, 2025

CORRESP May 12, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.

As filed with the U.S. Securities and Exchange Commission on May 8, 2025

S-4/A As filed with the U.S. Securities and Exchange Commission on May 8, 2025 Registration No. 333-284787 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TUHURA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 2834 99-0360497 (State of Incorporation) (Primary

Form of Proxy Card of TuHURA Biosciences, Inc.

EX-99.1 Exhibit 99.1 ☐        TUHURA BIOSCIENCES, INC. SPECIAL MEETING OF STOCKHOLDERS [ ], 2025 THIS PROXY IS BEING SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints XXXX, as the undersigned’s proxy with full power of substitution, to represent and vote all of the shares which the undersigned is entitled to vote at the Special Meeting of Stockholders (t

Form of Proxy Card of Kineta, Inc.

EX-99.2 Exhibit 99.2 KINETA, INC. 7683 SE 27TH STREET, SUITE 481 MERCER ISLAND, WASHINGTON 98040   VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time the day before the meeting date. Follow the instructions to obtain your records

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 TuHURA Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorpora

Separation Agreement, dated May 5, 2025, between TuHURA Bioscience, Inc. and Dennis Yamashita (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 6, 2025)

Exhibit 10.1 SEPARATION AGREEMENT THIS SEPARATION AGREEMENT (this “Agreement”) is dated as of May 5, 2025, by and between DENNIS YAMASHITA, an individual whose address is [*] (“Employee”), and TuHURA Biosciences, Inc., a Nevada corporation, whose principal place of business is located at 10500 University Center Drive, Suite 110, Tampa, Florida 33612 (the “Company”). The Company and Employee are in

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission File

THE EMPLOYEE understands that this Agreement releases all claims based on facts or omissions occurring on or before the date of this Agreement, even if THE EMPLOYEE does not, at the time THE EMPLOYEE signs this Agreement, have knowledge of those fact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission File

Filing fee table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) TuHURA Biosciences, Inc.

First Amendment to the Agreement and Plan of Merger, dated May 5, 2025, by and among TuHURA, Kineta, the Merger Subs and the Stockholders Representative (incorporated by reference to Exhibit 2.2 of the Amendment No. 1 to Form S-4 Registration Statement filed on May 6, 2025).

EX-2.2 Exhibit 2.2 FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER THIS FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of May 5, 2025, is made and entered into by and among TuHURA Biosciences, Inc., a Nevada corporation (“Parent”), Hura Merger Sub I, Inc., a Delaware corporation and direct wholly-owned Subsidiary of Parent (“Merger Sub I”), Hura Merger Sub II, LLC, a

As filed with the U.S. Securities and Exchange Commission on May 6, 2025 Registration No. 333-284787 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT O

Table of Contents As filed with the U.S. Securities and Exchange Commission on May 6, 2025 Registration No. 333-284787 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TUHURA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 2834 99-0360497 (State of Incorporatio

* * *

CORRESP 100 N TAMPA ST SUITE 2700 TAMPA, FL 33602-5810 813.229.2300 TEL 813.221.4210 FAX FOLEY.COM May 6, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Jessica Dickerson   Joe McCann Re: TuHURA Biosciences, Inc.   Registration Statement on Form S-4   Filed February 7, 2025  

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP) Phase 1b/2a trial designed to evalu

Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: TuHURA Biosciences, Inc.

TuHURA Biosciences and Kineta Present Updated Results from Kineta’s Phase I-II Study of KVA12123 and TuHURA’s Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual

Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

425 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: TuHURA Biosciences, Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 TUHURA BIOSCIENCES,

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcino

Exhibit 99.1 TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025 MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement w

Insider Trading Policy

Exhibit 19.1 TUHURA BIOSCIENCES, INC. INSIDER TRADING COMPLIANCE POLICY AND PROCEDURES Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trade. Viol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 TUHURA BIOSCIE

TuHURA Biosciences, Inc. 2025 Non-Employee director Compensation Program (incorporated by reference to Exhibit 10.18 to the Annual Report on Form 10-K filed with the SEC on March 31, 2025)

Exhibit 10.18 TUHURA BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as of November 26, 2024) Non-employee members of the board of directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program sha

TuHURA Biosciences, Inc. Compensation Recovery Policy

Exhibit 97.1 TUHURA BIOSCIENCES, INC. INCENTIVE COMPENSATION CLAWBACK POLICY 1. Purpose. The purpose of this Recovery Policy (this “Policy”) is to describe the circumstances under which TuHURA Biosciences, Inc. (the “Company”) is required to or shall have the right to recover certain compensation paid to certain employees. Any references in compensation plans, agreements, equity awards or other po

Description of the Registrant's Securities

Exhibit 4.18 Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended As of December 31, 2024, TuHURA Biosciences, Inc. (“we”, “us” or the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, $0.001 par value per share. The following description o

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission F

Overcoming Resistance to Cancer Immunotherapy Presentation | March 2025 tuhurabio.com Filed by TuHURA Biosciences, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Act of 1934 Fi

Overcoming Resistance to Cancer Immunotherapy Presentation | March 2025 tuhurabio.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fi

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors Dr. Tendler

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors Dr. Tendler oversaw 30 Major Drug Approvals, including worldwide approvals for J&J’s transformational treatments in hematologic malignancies, prostate, lung and

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

Form of Secured Promissory Note (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on February 14, 2025)

SECURED PROMISSORY NOTE (Negotiable) Principal Amount: $[] Tampa, Florida , 2025 FOR VALUE RECEIVED, [●] (“Maker”), hereby promises to pay to TuHURA Biosciences, Inc.

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) TuHURA Biosciences, Inc.

Contingent Value Rights Agreement, dated October 18, 2024, by and between TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.) and Equiniti Trust Company, LLC

EX-10.1 2 d907296dex101.htm EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of October 18, 2024 (this “Agreement”), is entered into by and between Kintara Therapeutics, a Nevada corporation corporation (“Parent”), Equiniti Trust Company, LLC, as Rights Agent (the “Rights Agent”) and Robert Hoffman, solely in his capacity as the initial repres

As filed with the U.S. Securities and Exchange Commission on February 7, 2025 Registration No. 333-      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TUHURA B

Table of Contents As filed with the U.S. Securities and Exchange Commission on February 7, 2025 Registration No. 333-      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TUHURA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 2834 99-0360497 (State of Incorporation) (Primary Sta

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

Letter from Marcum LLP, dated December 31, 2024.

Exhibit 16.1 January 3, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.) under Item 4.01 of its Form 8-K dated January 3, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statem

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-8 (Form Type) TuHURA Biosciences, Inc.

Articles of Incorporation of TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.), as amended (incorporated by reference to Exhibit 4.1 to TuHURA’s Form S-8 filed with the SEC on December 23, 2024)

2 3 4 KINTARA THERAPEUTICS, INC. Certificate of Amendment to Articles of Incorporation (Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock) The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or a

As filed with the Securities and Exchange Commission on December 23, 2024

As filed with the Securities and Exchange Commission on December 23, 2024 Registration No.

Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 of TuHURA Biosciences, Inc.’s Current Report on Form 8-K filed with the SEC on December 12, 2024)

Exhibit 10.4 EXHIBIT B FORM OF LOCK-UP AGREEMENT December [●], 2024 TuHURA Biosciences, Inc. 10500 University Dr., Suite 110 Tampa, FL, United States 33612 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that TuHURA Biosciences, Inc., a Nevada corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of Decem

Form of Kineta, Inc. Support Agreement (incorporated by reference to Exhibit 10.3 of TuHURA Biosciences, Inc.’s Current Report on Form 8-K filed with the SEC on December 12, 2024)

Exhibit 10.3 EXHIBIT A-2 FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT TUHURA BIOSCIENCES, INC. THIS SUPPORT AGREEMENT (this “Agreement”), dated as of December [•], 2024, is made by and among TuHURA Biosciences, Inc., a Nevada corporation (“Parent”), Kineta, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of Parent.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 TUHURA BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA’s late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated

Exhibit 99.1 TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA’s late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and technology synergies build on TuHURA’s therapeutic focus on overcoming primary and acquired resistance

Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc., Kineta, Inc., Hura Merger Sub I, Inc., Hura Merger Sub II, LLC and Craig Philips (incorporated by reference to Exhibit 2.1 of TuHURA’s Current Report on Form 8-K filed with the SEC on December 12, 2024)

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among TUHURA BIOSCIENCES, INC., HURA MERGER SUB I, INC. HURA MERGER SUB II, LLC KINETA, INC. and CRAIG PHILIPS, solely in his capacity as STOCKHOLDERS REPRESENTATIVE Dated as of December 11, 2024 TABLE OF CONTENTS Page ARTICLE I THE MERGERS 2 Section 1.1 The Mergers 2 Section 1.2 Closing 3 Section 1.3 Effective Time 3 Section 1.4 Effects of the Mergers 3 Se

Clinical Trial Funding Agreement, dated December 11, 2024, between TuHURA Biosciences, Inc. and Kineta, Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on December 12, 2024)

Exhibit 10.1 CLINICAL TRIAL FUNDING AGREEMENT This Clinical Trial Funding Agreement (this “Agreement”) is made as of December 11, 2024 (the “Effective Date”), by and between TuHURA Biosciences, Inc., a Nevada corporation (“Lender”), and Kineta, Inc., a Delaware corporation (“Borrower”). RECITALS WHEREAS, Borrower is a clinical-stage biopharmaceutical company focused on identifying, acquiring, deve

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

Form of TuHURA Biosciences, Inc. Support Agreement (incorporated by reference to Exhibit 10.2 of TuHURA Biosciences, Inc.’s Current Report on Form 8-K filed with the SEC on December 12, 2024)

Exhibit 10.2 EXHIBIT A-1 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT KINETA, INC. THIS SUPPORT AGREEMENT (this “Agreement”), dated as of December [•], 2024, is made by and among TuHURA Biosciences, Inc., a Nevada corporation (“Parent”), Kineta, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the Company. WHEREA

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update IFx-2.0, a first-in-c

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

Form of TuHURA Biosciences, Inc. Stock Option Agreement under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on November 15, 2024)

TUHURA BIOSCIENCES, INC. 2024 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT You have been granted an option (this “Option”) to purchase shares of the common stock, par value $0.001 per share (the “Stock”), of TuHURA Biosciences, Inc. (the “Company”) pursuant to the Company’s 2024 Equity Incentive Plan (the “Plan”) and this Stock Option Award Agreement (this “Award Agreement”). This Option is grante

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 TuHURA Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37823 TuHURA Bi

September 30,

Exhibit 99.3 TUHURA BIOSCIENCES, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of September 30, 2024 and December 31, 2023 and for the three and nine months ended September 30 2024 and 2023. TUHURA BIOSCIENCES, INC AND SUBSIDIARY Condensed consolidated balance sheets As of September 30, 2024 (Unaudited), and December 31, 2023 Unaudited September 30, December 31, 2024 2023 Asse

Nine Months Ended September 30,

Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations of TuHURA Biosciences, Inc. (a Delaware corporation) The following discussion and analysis of the financial condition and results of operations of TuHURA Biosciences, Inc., a Delaware corporation (“TuHURA”), should be read in conjunction with its audited financial statements and interim unaudited fin

CA Patel F&F Investments, LLC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TUHURA BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 898920103 (CUSIP Number) October 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

Patel Vijay

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 TuHURA Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 898920103 (CUSIP Number) Vijay Patel K & V Investment One, LLC 6903 Congress St. New Port Richey, FL 34653 (941) 380-6942 (Name, Address and Telephone Number o

Theofilos Charles Steve

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TUHURA BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 898920103 (CUSIP Number) October 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

KP Biotech Group LLC

SC 13G 1 kpbiotech13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TUHURA BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 898920103 (CUSIP Number) October 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

Patel Samir Rashmikant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TUHURA BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 898920103 (CUSIP Number) October 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

Bianco James A.

SC 13D 1 bianco13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 TuHURA Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 898920103 (CUSIP Number) James Bianco President and Chief Executive Officer TuHURA Biosciences, Inc. 10500 University Drive, Suite 110 T

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information presents the combination of the financial information of Kintara and TuHURA adjusted to give effect to the Merger and related transactions. The following unaudited pro forma condensed combined financial information has been prepared in accordance with

Waiver Agreement to Agreement and Plan of Merger, dated as of October 18, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc.

Exhibit 2.3 WAIVER AGREEMENT This WAIVER AGREEMENT (this “Waiver”), dated as of October 18, 2024, is entered into by and among Kintara Therapeutics, Inc. (“Kintara”), Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara incorporated in the State of Delaware (“Merger Sub”), and TuHURA Biosciences, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein but not otherwise def

Three Months Ended March 31,

Exhibit 99.2 TUHURA MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of TuHURA’s financial condition and results of operations should be read together with TuHURA’s consolidated financial statements and the related notes appearing elsewhere in this proxy statement/prospectus. This discussion and other parts of this proxy st

List of Subsidiaries (incorporated by reference to Exhibit 21.1 to TuHURA Biosciences, Inc’s Current Report on Form 8-K filed with the SEC on October 21, 2024)

Exhibit 21.1 List of Subsidiaries Adgero Biopharmaceuticals Holdings, Inc. (Delaware) Adgero Biopharmaceuticals, Inc. (Delaware) TuHURA Biosciences, Inc. (Delaware)

Articles of Amendment to Articles of Incorporation of Kintara Therapeutics, Inc., as filed with the Secretary of State of Nevada, effective October 18, 2024 (Reverse Stock Split)

Exhibit 3.1

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Exhibit 99.1 TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics • Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer immunotherapy • Lead program entering single Phase 3 accelerated approval registration trial in first half of 2025 for treatment of 1st line Merkel Cell carcinoma under Special

Form of Indemnification Agreement by and between TuHURA Biosciences, Inc and each of its directors and executive officers (incorporated by reference to Exhibit 10.2 of TuHURA’s Current Report on Form 8-K filed with the SEC on October 21, 2024)

Exhibit 10.2 INDEMNITY AGREEMENT This Indemnity Agreement (this “Agreement”) dated as of , , is made by and between TuHURA Biosciences, Inc., a Nevada corporation (the “Company”), and (“Indemnitee”). Recitals A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company’s Bylaws, as amended (the “Bylaws”), pro

Articles of Amendment to the Articles of Incorporation of Kintara Therapeutics, Inc., as filed with the Secretary of State of Nevada, effective October 18, 2024 (Name Change Amendment)

Exhibit 3.2

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission

TuHURA Biosciences, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 of TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.) Current Report on Form 8-K filed with the SEC on October 21, 2024)

Exhibit 10.4 OMNIBUS EQUITY INCENTIVE PLAN TUHURA BIOSCIENCES, INC. 2024 EQUITY INCENTIVE PLAN 1. Purpose; Effective Date; Effect on Prior Plan. (a) Purpose. The TuHURA Biosciences, Inc. 2024 Equity Incentive Plan (the “Plan”) has two complementary purposes: (i) to attract and retain outstanding individuals to serve as officers, directors, employees, and consultants, and (ii) to increase stockhold

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissi

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Exhibit 99.1 Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 SAN DIEGO, CA, October 14, 2024 (GLOBE NEWSWIRE) - Kintara Therapeutics, Inc. (“Kintara”) (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a record dat

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Exhibit 99.1 Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 SAN DIEGO, CA, October 15, 2024 (GLOBE NEWSWIRE) - Kintara Therapeutics, Inc. (“Kintara”) (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissi

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information presents the combination of the financial information of Kintara and TuHURA adjusted to give effect to the Merger and related transactions. The following unaudited pro forma condensed combined financial information has been prepared in accordance with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 KINTARA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commissio

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commissio

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Exhibit 99.1 Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update SAN DIEGO, October 8, 2024/PRNewswire/ - Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal fourth quarter ended June 30, 2024, and pr

As filed with the Securities and Exchange Commission on October 8, 2024

As filed with the Securities and Exchange Commission on October 8, 2024 Registration Statement No.

June 30,

Exhibit 99.1 TUHURA BIOSCIENCES, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of June 30, 2024 and December 31, 2023 and for the three and six months ended June 30 2024 and 2023. TUHURA BIOSCIENCES, INC AND SUBSIDIARY Condensed consolidated balance sheets As of June 30, 2024 (Unaudited), and December 31, 2023 Unaudited June 30, December 31, 2024 2023 Assets Current Assets: Ca

Certificate, Amendment or Withdrawal of Designation of Kintara Therapeutics, Inc., relating to the Series C-3 Preferred Stock, filed with the Secretary of State of Nevada on October 4, 2024.*

Exhibit 3.26 FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate, Amendment or Withdrawal of Designation NRS 78.1955, 78.1955(6) Certificate of Designation Certificate of Amendment to Designation - Before Issuance of Class or Series Certificate of Amendment to Designation - After Issuance of Class or Serie

Amendment to Executive Employment Agreement, dated October 4, 2024, by and between the Company and Robert E. Hoffman*

Exhibit 10.32 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to Executive Employment Agreement (the “Amendatory Agreement”) is entered into effective as of October 4, 2024 (the “Effective Date”) by and between Kintara Therapeutics, Inc., a Nevada corporation (the “Company”) and Robert E. Hoffman (“Executive”). WHEREAS, Executive currently serves as Chief Executive Officer, President, a

List of Subsidiaries*

Exhibit 21.1 List of Subsidiaries Del Mar Pharmaceuticals (BC) Ltd. (British Columbia, Canada) 0959454 B.C. Ltd. (British Columbia, Canada) 0959456 B.C. Ltd. (British Columbia, Canada) Adgero Biopharmaceuticals Holdings, Inc. (Delaware) Adgero Biopharmaceuticals, Inc. (Delaware) Kayak Mergeco, Inc.

Certificate, Amendment or Withdrawal of Designation of Kintara Therapeutics, Inc., relating to the Series C-2 Preferred Stock, filed with the Secretary of State of Nevada on October 4, 2024.*

Exhibit 3.25 FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate, Amendment or Withdrawal of Designation NRS 78.1955, 78.1955(6) Certificate of Designation Certificate of Amendment to Designation - Before Issuance of Class or Series Certificate of Amendment to Designation - After Issuance of Class or Serie

Certificate, Amendment or Withdrawal of Designation of Kintara Therapeutics, Inc., relating to the Series C-1 Preferred Stock, filed with the Secretary of State of Nevada on October 4, 2024.*

Exhibit 3.24 FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate, Amendment or Withdrawal of Designation NRS 78.1955, 78.1955(6) Certificate of Designation Certificate of Amendment to Designation - Before Issuance of Class or Series Certificate of Amendment to Designation - After Issuance of Class or Serie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K

srp UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-37823 Kintara Therapeutics, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one):  ☒ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: June 30, 2024 ☐

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one):  ☒ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

SUPPLEMENT DATED SEPTEMBER 25, 2024 TO THE PROXY STATEMENT/PROSPECTUS DATED AUGUST 19, 2024

Filed pursuant to 424(b)(3) Registration No. 333-279368 SUPPLEMENT DATED SEPTEMBER 25, 2024 TO THE PROXY STATEMENT/PROSPECTUS DATED AUGUST 19, 2024 September 25, 2024 Dear Kintara and TuHURA Stockholders: As previously announced, Kintara Therapeutics, Inc. (“Kintara”), Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara incorporated in the State of Delaware (“Merger Sub”), and TuHURA Bioscie

Waiver Agreement to Agreement and Plan of Merger, dated as of September 25, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc.

Exhibit 2.1 WAIVER AGREEMENT This WAIVER AGREEMENT (this “Waiver”), dated as of September 25, 2024, is entered into by and among Kintara Therapeutics, Inc. (“Kintara”), Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara incorporated in the State of Delaware (“Merger Sub”), and TuHURA Biosciences, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein but not otherwise d

Waiver Agreement to Agreement and Plan of Merger, dated as of September 25, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc.

Exhibit 2.1 WAIVER AGREEMENT This WAIVER AGREEMENT (this “Waiver”), dated as of September 25, 2024, is entered into by and among Kintara Therapeutics, Inc. (“Kintara”), Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara incorporated in the State of Delaware (“Merger Sub”), and TuHURA Biosciences, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein but not otherwise d

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

For assistance with voting your shares, contact Alliance Advisors at 1-(866)-619-8907 North America, or +1 (551)-210-9859 if international.

Exhibit 99.1 It is imperative for ALL stockholders to VOTE your shares. Voting deadline is October 3rd at 11:59 p.m., EST Kintara Therapeutics, Inc. (“Kintara”) has adjourned their Special Meeting of Stockholders until October 4, 2024 at 9:00 a.m. (EST) because the voting threshold has not been reached on Proposals 3 & 5 (as described in Kintara’s definitive proxy statement and final prospectus fi

For assistance with voting your shares, contact Alliance Advisors at 1-(866)-619-8907 North America, or +1 (551)-210-9859 if international.

Exhibit 99.1 It is imperative for ALL stockholders to VOTE your shares. Voting deadline is October 3rd at 11:59 p.m., EST Kintara Therapeutics, Inc. (“Kintara”) has adjourned their Special Meeting of Stockholders until October 4, 2024 at 9:00 a.m. (EST) because the voting threshold has not been reached on Proposals 3 & 5 (as described in Kintara’s definitive proxy statement and final prospectus fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Exhibit 99.1 Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 SAN DIEGO – September 20, 2024 – Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it adjourned the Special Meeting of Stockholders (the “Special Meeting”) held on September

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Exhibit 99.1 Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 SAN DIEGO – September 20, 2024 – Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it adjourned the Special Meeting of Stockholders (the “Special Meeting”) held on September

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

Social Media Posts.

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

Social Media Posts.

Exhibit 99.1

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Exhibit 99.1 Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences • Stockholders must vote by 11:59 p.m. ET on September 19, 2024 for their vote to count • A “FOR” vote on Proposals 3 & 5 by holders of a majority of the voting power of Kintara’s outstanding shares as of August 14, 2024 is required to allow for completi

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Exhibit 99.1 Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences • Stockholders must vote by 11:59 p.m. ET on September 19, 2024 for their vote to count • A “FOR” vote on Proposals 3 & 5 by holders of a majority of the voting power of Kintara’s outstanding shares as of August 14, 2024 is required to allow for completi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Exhibit 99.1 Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study SAN DIEGO, September 11, 2024 /PRNewswire/ - Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today provided a corporate and REM-001 clinical study update. Corporate Updates • In April 2024, Kintara

It is imperative for ALL stockholders to VOTE your shares.

Exhibit 99.2 It is imperative for ALL stockholders to VOTE your shares. Voting deadline is September 19th at 11:59 p.m., EST Clinical Trial in Breast Cancer Treatment Information about Kintara’s trial: Patients with cutaneous metastatic breast cancer have limited treatment options. The suspension of Kintara’s clinical trial would have an adverse effect on the progress that is being made in the stu

It is imperative for ALL stockholders to VOTE your shares.

Exhibit 99.2 It is imperative for ALL stockholders to VOTE your shares. Voting deadline is September 19th at 11:59 p.m., EST Clinical Trial in Breast Cancer Treatment Information about Kintara’s trial: Patients with cutaneous metastatic breast cancer have limited treatment options. The suspension of Kintara’s clinical trial would have an adverse effect on the progress that is being made in the stu

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Exhibit 99.1 Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study SAN DIEGO, September 11, 2024 /PRNewswire/ - Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today provided a corporate and REM-001 clinical study update. Corporate Updates • In April 2024, Kintara

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

Exhibit 99.1 Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. • Stockholders must vote by 11:59 p.m., Eastern Time, on September 19, 2024, for their vote to count SAN DIEGO – September 9, 2024 – Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara") a biopharmaceutical company focused on the development of new

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commiss

Your Shareholder Vote is Needed — NOW!

Alliance Advisors 200 Broadacres Drive, 3rd Fl. Bloomfield, NJ 07003 Exhibit 99.2 Your Shareholder Vote is Needed — NOW! The Kintara Board of Directors has called the special meeting to allow for the completion of the proposed merger with TuHURA Biosciences, Inc. The Board of Directors believes the proposed merger will result in a publicly traded company with a promising therapeutic pipeline, a st

Your Shareholder Vote is Needed — NOW!

Alliance Advisors 200 Broadacres Drive, 3rd Fl. Bloomfield, NJ 07003 Exhibit 99.2 Your Shareholder Vote is Needed — NOW! The Kintara Board of Directors has called the special meeting to allow for the completion of the proposed merger with TuHURA Biosciences, Inc. The Board of Directors believes the proposed merger will result in a publicly traded company with a promising therapeutic pipeline, a st

It is imperative for ALL stockholders to VOTE your shares.

Exhibit 99.3 It is imperative for ALL stockholders to VOTE your shares. Voting deadline is September 19th at 11:59 p.m., EST Your voting support on all proposals is vital to allow for completion of the proposed merger with TuHURA Biosciences, Inc. (“TuHURA”). The Kintara Board of Directors believes the proposed merger represents the best path forward for Kintara stockholders and has the potential

It is imperative for ALL stockholders to VOTE your shares.

Exhibit 99.3 It is imperative for ALL stockholders to VOTE your shares. Voting deadline is September 19th at 11:59 p.m., EST Your voting support on all proposals is vital to allow for completion of the proposed merger with TuHURA Biosciences, Inc. (“TuHURA”). The Kintara Board of Directors believes the proposed merger represents the best path forward for Kintara stockholders and has the potential

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

Exhibit 99.1 Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. • Stockholders must vote by 11:59 p.m., Eastern Time, on September 19, 2024, for their vote to count SAN DIEGO – September 9, 2024 – Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara") a biopharmaceutical company focused on the development of new

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 03, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 03, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commis

Please vote as soon as possible to ensure your vote is represented at the special meeting to be held on September 20, 2024. For assistance with voting your shares, contact Alliance Advisors at (866)-619-8907 North America, or +1 (551)-210-9859 if int

Exhibit 99.1 We ask that ALL Kintara stockholders VOTE their shares TODAY! Voting deadline is September 19th at 11:59 p.m., EST Your vote “FOR” each proposal will allow for the completion of the proposed merger with TuHURA Biosciences, Inc. (“TuHURA”). If less than a majority of our outstanding shares are voted FOR Proposals 3 & 5, the proposed merger with TuHURA cannot be completed. Without stock

Please vote as soon as possible to ensure your vote is represented at the special meeting to be held on September 20, 2024. For assistance with voting your shares, contact Alliance Advisors at (866)-619-8907 North America, or +1 (551)-210-9859 if int

Exhibit 99.1 We ask that ALL Kintara stockholders VOTE their shares TODAY! Voting deadline is September 19th at 11:59 p.m., EST Your vote “FOR” each proposal will allow for the completion of the proposed merger with TuHURA Biosciences, Inc. (“TuHURA”). If less than a majority of our outstanding shares are voted FOR Proposals 3 & 5, the proposed merger with TuHURA cannot be completed. Without stock

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer 30 of a projected 39 patients have been enrolled in the clinical trial t

Exhibit 99.1 TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer 30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck’s anti-PD1 therapy, KEYTRU

KINTARA THERAPEUTICS, INC. 9920 Pacific Heights Blvd, Suite 150 San Diego, CA 92130

Table of Contents Filed pursuant to 424(b)(3) Registration No. 333-279368 KINTARA THERAPEUTICS, INC. 9920 Pacific Heights Blvd, Suite 150 San Diego, CA 92130 To the Stockholders of Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc., On behalf of the Kintara Therapeutics, Inc. (“Kintara”) board of directors, we are pleased to enclose the proxy statement/prospectus for the proposed acquisition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commissio

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer 30 of a projected 39 patients have been enrolled in the clinical trial t

Exhibit 99.1 TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer 30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck’s anti-PD1 therapy, KEYTRU

August 12, 2024

August 12, 2024 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D.

As filed with the Securities and Exchange Commission on August 12, 2024

As filed with the Securities and Exchange Commission on August 12, 2024 Registration Statement No.

As filed with the Securities and Exchange Commission on August 8, 2024

S-4/A Table of Contents As filed with the Securities and Exchange Commission on August 8, 2024 Registration Statement No.

Form of Proxy Card of Kintara Therapeutics, Inc.

Exhibit 99.1 PROXY KINTARA THERAPEUTICS, INC. PROXY FOR SPECIAL MEETING OF STOCKHOLDERS TO BE HELD XXXX XX, XXXX THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED The undersigned hereby constitutes and appoints XXXX, as the undersigned’s proxy with full power of substitution, to represent and vote all of the shares which the undersigned

August 8, 2024

August 8, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.

Form of TuHURA Biosciences, Inc. Series A Preferred Stock Warrant Amendment Agreement (incorporated by reference to Exhibit 4.19 to the Registration Statement on Form S-4/A filed on August 8, 2024 (Registration No. 333-279368))

Exhibit 4.19 TUHURA BIOSCIENCES, INC. WARRANT AMENDMENT AGREEMENT THIS WARRANT AMENDMENT AGREEMENT (this “Amendment”) is made and entered into effective as of August 9, 2024 (the “Effective Date”), by and between TUHURA BIOSCIENCES, INC., a Delaware corporation (the “Company”), and the undersigned holder of Outstanding Warrants (as defined below) (the “Holder”). RECITALS A. In connection with and

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-4 KINTARA THERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock 4

As filed with the Securities and Exchange Commission on July 19, 2024 Registration Statement No. 333-279368 UNITED STATES SECURITIES AND EXCHANGE C O MMISSION Washington , D.C. 20549 Amendment No. 2 to Form S-4 REGISTRATION STATEMENT UNDER THE SECURI

Table of Contents As filed with the Securities and Exchange Commission on July 19, 2024 Registration Statement No.

July 19, 2024

July 19, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.

Exclusivity and Right of First Offer Agreement, dated July 3, 2024, between TuHURA Biosciences, Inc. and Kineta, Inc. (incorporated by reference to Exhibit 10.41 to the Registration Statement on Form S-4/A filed on July 19, 2024 (Registration No. 333-279368))

Exhibit 10.41 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVITY AND RIGHT OF FIRST OFFER AGREEMENT THIS EXCLUSIVITY AND RIGHT OF FIRST OFFER AGREEMENT (this “Agreement”) is made and dated as of July 3, 2024 (the “Effective Dat

Certificate, Amendment or Withdrawal of Designation of Kintara Therapeutics, Inc., relating to the Special Voting Preferred Stock, filed with the Secretary of State of Nevada on July 12, 2024 (as incorporated by reference to Exhibit 3.1 of Kintara’s Current Report on Form 8-K filed with the SEC on June 12, 2024)

Exhibit 3.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 KINTARA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission

Certificate, Amendment or Withdrawal of Designation of Kintara Therapeutics, Inc., relating to the Series B Preferred Stock, filed with the Secretary of State of Nevada on July 12, 2024 (as incorporated by reference to Exhibit 3.2 of Kintara’s Current Report on Form 8-K filed with the SEC on June 12, 2024)

Exhibit 3.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 KINTARA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission F

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppre

Exhibit 99.1 TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppre

Exhibit 99.1 TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 KINTARA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 KINTARA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission F

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

Exhibit 99.1 Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones SAN DIEGO, July 1, 2024 /PRNewswire/ - Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, and TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

Exhibit 99.1 Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones SAN DIEGO, July 1, 2024 /PRNewswire/ - Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, and TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 KINTARA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission F

As filed with the Securities and Exchange Commission on June 2 7 , 2024 Registration Statement No. 333-279368 UNITED STATES SECURITIES AND EXCHANGE C O MMISSION Washington, D.C. 20549 Amendment No. 1 to Form S-4 REGISTRATION STATEMENT UNDER THE SECUR

Table of Contents As filed with the Securities and Exchange Commission on June 2 7 , 2024 Registration Statement No.

June 27, 2024

June 27, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 KINTARA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 KINTARA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 KINTARA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (c

Exhibit 99.1 TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) TuHURA’s lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeks Eighty percent (80%) of ICI naïve pa

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (c

Exhibit 99.1 TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) TuHURA’s lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeks Eighty percent (80%) of ICI naïve pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 KINTARA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 KINTARA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 KINTARA THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT U

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37823 Kintara Thera

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

Exhibit 99.1 Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results SAN DIEGO, May 14, 2024/PRNewswire/ - Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate deve

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission F

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

Exhibit 99.1 Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results SAN DIEGO, May 14, 2024/PRNewswire/ - Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate deve

Consent of James Manuso, Ph.D, MBA to serve as a director of Kintara Therapeutics, Inc., to be renamed TuHURA Biosciences, Inc.

Exhibit 99.3 Consent of Proposed Director I, James Manuso, hereby consent to the following: • to serve as a director of Kintara Therapeutics, Inc., to be renamed TuHURA Biosciences, Inc., if the transactions contemplated by the Agreement and Plan of Merger, dated April 2, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc., are consummated, including th

Consent of Lucid Capital Markets, LLC

Exhibit 99.2 Consent of Lucid Capital Markets, LLC May 13, 2024 Board of Directors Kintara Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 150 San Diego, CA 92121 Re: Registration Statement on Form S-4 of Kintara Therapeutics, Inc. Members of the Board: We hereby consent to the inclusion of our opinion letter, dated April 2, 2024, to the Board of Directors of Kintara Therapeutics, Inc. (“Kinta

Amendment to Certificate of Incorporation of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.), as currently in effect.

Exhibit 3.21 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF MORPHOGENESIS, INC. Morphogenesis, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), by its duly authorized officer, hereby certifies as follows: FIRST: Pursuant to Section 242 of the Delaware General Corporation Law (the “DGCL”), this Certificate of Amendment (the “Am

Exclusive License Agreement, dated April 23, 2021, between Morphogenesis, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc., as amended (incorporated by reference to Exhibit 10.38 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368)

Exhibit 10.38 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVE LICENSE AGREEMENT THIS AGREEMENT is made and entered into on April 23, 2021 (hereinafter “EFFECTIVE DATE”) by and between H. Lee Moffitt Cancer Center and Research

Form of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.) Common Stock Purchase Warrant issued in Note Conversion Transaction (incorporated by reference to Exhibit 4.15 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 4.15 NEITHER THE ISSUANCE OF THIS WARRANT NOR THE ISSUANCE OF THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAS BEEN REGISTERED UNDER THE ACT OR ANY APPLICABLE STATE LAWS REGULATING THE SALE OF SECURITIES. NO INTEREST IN THIS WARRANT MAY BE SOLD, TRANSFERRED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE DISTRIBUTED UNLESS (I) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDE

Second Amended and Restated Employment Agreement, dated March 29, 2024, between TuHURA Biosciences, Inc. and James Bianco, M.D (incorporated by reference to Exhibit 10.35 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 10.35 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Second Amended and Restated Employment Agreement (this “Agreement”) is made this 29th day of March, 2024 by and between James Bianco, MD (“Employee”), and Tuhura Biosciences, Inc., a Delaware corporation f/k/a Morphogenesis, Inc. (the “Company”). Employee and the Company are hereinafter sometimes referred to individually as a “Par

Form of Convertible Promissory Note issued in TuHURA Note Financing

Exhibit 4.18 THIS NOTE AND THE SECURITIES INTO WHICH THE NOTE MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE OR SOLD, ASSIGNED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION UNLESS WRITTEN EVIDENCE REASONABLY SATISFACTORY TO THE COMPANY IS SUPPLIED TO THE

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-4 KINTARA THERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock 4

Form of Option Agreement under the Amended and Restated Equity Plan of Morphogenesis, Inc.

Exhibit 10.33 MORPHOGENESIS, INC. STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (this “Option Agreement”) is entered into as of [] (the “Grant Date”) between Morphogenesis, Inc., a Florida corporation (the “Company”), and [] (the “Optionee). This option is being granted pursuant to the terms of the Company’s 2019 Restated Stock Option Plan, as the same may be amended from time to time (the “P

Form of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.) Common Stock Purchase Warrant, dated June 1, 2019, issued for advisory services (incorporated by reference to Exhibit 4.13 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 4.13 WARRANT No.A-[] This Warrant and the securities issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Act”), or qualified under any state or foreign securities laws and may not be offered for sale, sold, pledged, hypothecated or otherwise transferred or assigned unless (i) a registration statement covering such shares is eff

Form of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.) Common Stock Purchase Warrant issued in Series B Preferred Stock Offering (incorporated by reference to Exhibit 4.16 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 4.16 NEITHER THE ISSUANCE OF THIS WARRANT NOR THE ISSUANCE OF THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAS BEEN REGISTERED UNDER THE ACT OR ANY APPLICABLE STATE LAWS REGULATING THE SALE OF SECURITIES. NO INTEREST IN THIS WARRANT MAY BE SOLD, TRANSFERRED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE DISTRIBUTED UNLESS (I) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDE

Form of TuHURA Biosciences, Inc. Common Stock Warrant issued in TuHURA Note Financing (incorporated by reference to Exhibit 4.17 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 4.17 THIS WARRANT AND THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE SE

Consent of George Ng to serve as a director of Kintara Therapeutics, Inc., to be renamed TuHURA Biosciences, Inc.

Exhibit 99.6 Consent of Proposed Director I, George Ng, hereby consent to the following: • to serve as a director of Kintara Therapeutics, Inc., to be renamed TuHURA Biosciences, Inc., if the transactions contemplated by the Agreement and Plan of Merger, dated April 2, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc., are consummated, including the m

Employment Agreement, dated December 19, 2023, between TuHURA Biosciences, Inc. and Dennis Yamashita

Exhibit 10.36 EMPLOYMENT AGREEMENT This Agreement (this “Agreement”) is made this 19th day of December, 2023 by and between Dennis Yamashita (“Employee”) and TuHURA Biosciences, Inc. (the “Company”). Employee and the Company are hereinafter sometimes referred to individually as a “Party” and collectively as the “Parties.” WITNESSETH: WHEREAS, pursuant to the Original Employment Agreement, the Comp

Exclusive License Agreement, dated March 29, 2019, between Morphogenesis, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc., as amended (incorporated by reference to Exhibit 10.37 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 10.37 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVE LICENSE AGREEMENT THIS AGREEMENT is made and entered into on March 29, 2019 (hereinafter “EFFECTIVE DATE”) by and between H. Lee Moffitt Cancer Center and Research

Certificate of Incorporation of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.), as currently in effect.

Exhibit 3.20 CERTIFICATE OF INCORPORATION OF MORPHOGENESIS, INC. I. NAME The name of the corporation is Morphogenesis, Inc. (the “Corporation”). II. REGISTERED OFFICE AND AGENT The address of the Corporation’s registered office is 251 Little Falls Drive, Wilmington, DE 19808, New Castle County. The name of the registered agent at such address is Corporation Service Company. III. PURPOSE The nature

Amended and Restated Equity Plan of Morphogenesis, Inc.

Exhibit 10.32 Amended & Restated EQUITY INCENTIVE PLAN Morphogenesis, Inc. Adopted on January 13, 2019 1. Purpose The purpose of this Amended and Restated Equity Incentive Plan (the “Plan”) of Morphogenesis, Inc., a Florida corporation (the “Company”), is to amend, update and restate the terms of the existing 2016 Stock Option Plan to advance the interests of the Company’s stockholders by enhancin

Form of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.) Common Stock Purchase Warrant issued in Series A Preferred Offering (incorporated by reference to Exhibit 4.12 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 4.12 NEITHER THE ISSUANCE OF THIS WARRANT NOR THE ISSUANCE OF THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAS BEEN REGISTERED UNDER THE ACT OR ANY APPLICABLE STATE LAWS REGULATING THE SALE OF SECURITIES. NO INTEREST IN THIS WARRANT MAY BE SOLD, TRANSFERRED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE DISTRIBUTED UNLESS (I) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDE

Consent of Alan List, M.D. to serve as a director of Kintara Therapeutics, Inc., to be renamed TuHURA Biosciences, Inc.

Exhibit 99.5 Consent of Proposed Director I, Alan List, M.D., hereby consent to the following: • to serve as a director of Kintara Therapeutics, Inc., to be renamed TuHURA Biosciences, Inc., if the transactions contemplated by the Agreement and Plan of Merger, dated April 2, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc., are consummated, including

Restated and Amended Exclusive License Agreement, effective September 7, 2022, between TuHURA Biopharma, Inc. and West Virginia Research Corporation (incorporated by reference to Exhibit 10.39 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 10.39 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED RESTATED AND AMENDED EXCLUSIVE LICENSE AGREEMENT This Restated and Amended Exclusive License Agreement (“Agreement”), to be effective as of September 7, 2022 (“Effective Date

Form of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.) Common Stock Purchase Warrant issued in Series A-1 Preferred Stock Offering (incorporated by reference to Exhibit 4.14 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 4.14 NEITHER THE ISSUANCE OF THIS WARRANT NOR THE ISSUANCE OF THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAS BEEN REGISTERED UNDER THE ACT OR ANY APPLICABLE STATE LAWS REGULATING THE SALE OF SECURITIES. NO INTEREST IN THIS WARRANT MAY BE SOLD, TRANSFERRED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE DISTRIBUTED UNLESS (I) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDE

As filed with the Securities and Exchange Commission on May 13, 2024

S-4 Table of Contents As filed with the Securities and Exchange Commission on May 13, 2024 Registration Statement No.

Consent of James Bianco, M.D. to serve as a director of Kintara Therapeutics, Inc., to be renamed TuHURA Biosciences, Inc.

Exhibit 99.4 Consent of Proposed Director I, James Bianco, M.D., hereby consent to the following: • to serve as a director of Kintara Therapeutics, Inc., to be renamed TuHURA Biosciences, Inc., if the transactions contemplated by the Agreement and Plan of Merger, dated April 2, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc., are consummated, includ

Bylaws of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.), as currently in effect.

Exhibit 3.22 BYLAWS OF MORPHOGENESIS, INC. (As adopted by unanimous vote of the Board of Directors effective April 27, 2023) The provisions of these bylaws are subject and subordinate to the corporation’s certificate of incorporation. If any provisions of these bylaws are in conflict with the provisions of the certificate of incorporation, the provisions of the certificate of incorporation shall c

Second Amended and Restated Employment Agreement, dated March 29, 2024, between TuHURA Biosciences, Inc. and Dan Dearborn (incorporated by reference to Exhibit 10.34 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 10.34 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Second Amended and Restated Employment Agreement (this “Agreement”) is made this 29th day of March, 2024 by and between Dan Dearborn (“Employee”) and Tuhura Biosciences, Inc., a Delaware corporation f/k/a Morphogenesis, Inc. (the “Company”). Employee and the Company are hereinafter sometimes referred to individually as a “Party” a

Asset Purchase Agreement, dated January 26, 2023, between TuHURA Biopharma Inc. and Morphogenesis, Inc. (incorporated by reference to Exhibit 10.40 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368))

Exhibit 10.40 ASSET PURCHASE AGREEMENT BY AND BETWEEN TUHURA BIOPHARMA INC. AND MORPHOGENESIS, INC. DATED AS OF JANUARY 26, 2023 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE 1 Section 1.01 Purchase and Sale of Assets 1 Section 1.02 Excluded Assets 2 Section 1.03 Assumed Liabilities 2 Section 1.04 Excluded Liabilities 3 Section 1.05 Purchase Price 3 Section 1.06 Payment of the Purchase Price

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2024 KINTARA THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission Fi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission

TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Exhibit 99.1 TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, FL & SAN DIEGO, CA, April 25, 2024 –TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today annou

TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Exhibit 99.1 TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, FL & SAN DIEGO, CA, April 25, 2024 –TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today annou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 KINTARA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission

Form of Lock-Up Agreement

Exhibit 10.3 FORM OF LOCK-UP AGREEMENT April [●], 2024 Kintara Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 150 San Diego, CA, United States 92121 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Kintara Therapeutics, Inc., a Nevada corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of April

Agreement and Plan of Merger, dated as of April 2, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc., as amended (incorporated by reference to Exhibit 2.1 of TuHURA’s (f/k/a Kintara Therapeutics, Inc.) Current Report on Form 8-K filed with the SEC on April 3, 2024)

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among KINTARA THERAPEUTICS, INC., KAYAK MERGECO, INC. and TUHURA BIOSCIENCES, INC. Dated as of April 2, 2024 TABLE OF CONTENTS Page ARTICLE I CERTAIN GOVERNANCE MATTERS 3 Section 1.1 Parent Matters 3 Section 1.2 Surviving Company Matters 3 ARTICLE II THE MERGER 4 Section 2.1 Incorporation of Merger Sub 4 Section 2.2 The Merger 4 Sec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 KINTARA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

Exhibit 99.1 Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement • TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA’s accelerated approval pathway • $31 million subscribed financing by TuHURA in connection with

Form of Contingent Value Rights Agreement

Exhibit 10.4 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●], 2024 (this “Agreement”), is entered into by and between Kintara Therapeutics, a Nevada corporation corporation (“Parent”), Mountain Share Transfer, LLC, as Rights Agent (the “Rights Agent”) and Robert Hoffman, solely in his capacity as the initial representative, agent and attorney-in-fa

Form of TuHURA Support Agreement (incorporated by reference to Exhibit 10.2 of Kintara’s Current Report on Form 8-K filed with the SEC on April 3, 2024)

Exhibit 10.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT TUHURA BIOSCIENCES, INC. THIS SUPPORT AGREEMENT (this “Agreement”), dated as of April [●], 2024, is made by and among Kintara Therapeutics, Inc., a Nevada corporation (“Parent”), TuHURA Biosciences, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the Comp

Form of Kintara Support Agreement (incorporated by reference to Exhibit 10.1 of Kintara’s Current Report on Form 8-K filed with the SEC on April 3, 2024)

Exhibit 10.1 FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT KINTARA THERAPEUTICS, INC. THIS SUPPORT AGREEMENT (this “Agreement”), dated as of April [●], 2024, is made by and among Kintara Therapeutics, Inc., a Nevada corporation (“Parent”), TuHURA Biosciences, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of Parent.

Project Kayak Conference Call Script

Exhibit 99.2 Project Kayak Conference Call Script Slide 1 (Operator) Hello and welcome to the Kintara and TuHURA conference call and webcast. As a brief reminder, all participants are currently in a listen-only mode. If anyone requires operator assistance during the event, please press star zero on your telephone keypad. Slide 2 (Operator) At this time, I'd like to remind our listeners that, excep

Enter into Definitive Merger Agreement Phase 3 Clinical Stage Immuno-Oncology Company Addressing Major Obstacles to Overcoming Resistance to Cancer Immunotherapy

Enter into Definitive Merger Agreement Phase 3 Clinical Stage Immuno-Oncology Company Addressing Major Obstacles to Overcoming Resistance to Cancer Immunotherapy Forward-Looking Statements This presentation contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995.

Enter into Definitive Merger Agreement Phase 3 Clinical Stage Immuno-Oncology Company Addressing Major Obstacles to Overcoming Resistance to Cancer Immunotherapy

Enter into Definitive Merger Agreement Phase 3 Clinical Stage Immuno-Oncology Company Addressing Major Obstacles to Overcoming Resistance to Cancer Immunotherapy Forward-Looking Statements This presentation contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995.

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

Exhibit 99.1 Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement • TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA’s accelerated approval pathway • $31 million subscribed financing by TuHURA in connection with

Form of Contingent Value Rights Agreement (incorporated by reference to Exhibit 10.4 of Kintara’s Current Report on Form 8-K filed with the SEC on April 3, 2024)

Exhibit 10.4 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●], 2024 (this “Agreement”), is entered into by and between Kintara Therapeutics, a Nevada corporation corporation (“Parent”), Mountain Share Transfer, LLC, as Rights Agent (the “Rights Agent”) and Robert Hoffman, solely in his capacity as the initial representative, agent and attorney-in-fa

Form of Lock-up Agreement (incorporated by reference to Exhibit 10.3 of Kintara’s Current Report on Form 8-K filed with the SEC on April 3, 2024)

Exhibit 10.3 FORM OF LOCK-UP AGREEMENT April [●], 2024 Kintara Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 150 San Diego, CA, United States 92121 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Kintara Therapeutics, Inc., a Nevada corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of April

Project Kayak Conference Call Script

Exhibit 99.2 Project Kayak Conference Call Script Slide 1 (Operator) Hello and welcome to the Kintara and TuHURA conference call and webcast. As a brief reminder, all participants are currently in a listen-only mode. If anyone requires operator assistance during the event, please press star zero on your telephone keypad. Slide 2 (Operator) At this time, I'd like to remind our listeners that, excep

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 KINTARA THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commission

Form of Kintara Support Agreement

Exhibit 10.1 FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT KINTARA THERAPEUTICS, INC. THIS SUPPORT AGREEMENT (this “Agreement”), dated as of April [●], 2024, is made by and among Kintara Therapeutics, Inc., a Nevada corporation (“Parent”), TuHURA Biosciences, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of Parent.

Agreement and Plan of Merger, dated as of April 2, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc.

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among KINTARA THERAPEUTICS, INC., KAYAK MERGECO, INC. and TUHURA BIOSCIENCES, INC. Dated as of April 2, 2024 TABLE OF CONTENTS Page ARTICLE I CERTAIN GOVERNANCE MATTERS 3 Section 1.1 Parent Matters 3 Section 1.2 Surviving Company Matters 3 ARTICLE II THE MERGER 4 Section 2.1 Incorporation of Merger Sub 4 Section 2.2 The Merger 4 Sec

Form of TuHURA Support Agreement

Exhibit 10.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT TUHURA BIOSCIENCES, INC. THIS SUPPORT AGREEMENT (this “Agreement”), dated as of April [●], 2024, is made by and among Kintara Therapeutics, Inc., a Nevada corporation (“Parent”), TuHURA Biosciences, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the Comp

March 13, 2024

RW March 13, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 KINTARA THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 KINTARA THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 001-37823 99-0360497 (State or other jurisdiction of incorporation) (Commiss